Current controversyControversies in lung transplantation: management of cytomegalovirus infections
Section snippets
Risk of cytomegalovirus infection and disease in lung transplant recipients
It is difficult to determine the exact incidence of CMV infection or disease from the published lung transplant literature due to differences in the definition of CMV infection and disease, immunosuppressive protocols, CMV prophylactic regimens, the lack of risk stratification by CMV serostatus, the evolution of monitoring techniques and the duration of follow-up. The reported incidence of CMV infection and disease following lung transplantation in the post-GCV era ranges from 35% to 86% with
Cytomegalovirus and bronchiolitis obliterans syndrome
The major limiting factor for long-term survival after lung transplantation is bronchiolitis obliterans syndrome (BOS). Recognized risk factors for the development of BOS are the number and severity of acute rejection episodes as well as late-occurring episodes. Several studies suggest that CMV pneumonitis and positive CMV serology are risk factors for BOS.2, 11, 12 However, other reports have not found these same associations.13, 14 CMV may induce allograft injury by direct tissue invasion and
Strategies to prevent cytomegalovirus infection
Three potential mechanisms of CMV infection have been recognized: transmission by the donor organ; transmission by blood products; or reactivation of latent virus in the recipient. The presence of antibody to CMV in the recipient, whether endogenous or passively transferred, appears to provide protection against the development of serious and sometimes fatal disease. In the absence of endogenous antibody protection, primary CMV infections, particularly CMV pneumonitis or gastrointestinal
Techniques to monitor for cytomeglovirus infection
Rapid and accurate diagnostic tests are critical for the appropriate management of CMV following lung transplantation. Diagnostic tests for CMV have undergone rapid evolution since the early 1990s. Initially, most programs followed seroconversion as measured by rising antibody titers or surveillance cultures of blood, throat swabs or urine.2 With the exception of blood cultures, these methods were soon found to be insensitive predictors of CMV disease. Many reports soon appeared advocating the
Prophylaxis of cytomegalovirus infection
Prior to the development of effective anti-viral agents, CMV caused illness in the majority of lung transplant recipients, and primary infection in D+/R− recipients was associated with severe and often life-threatening disease.7 Following the development of GCV it soon became clear that the short-term morbidity and mortality of CMV infections could be controlled with therapeutic courses of intravenous GCV. Several investigators then sought to determine whether prophylactic use of GCV or other
Pre-emptive therapy
Some centers have advocated pre-emptive therapy based on detection of CMV antigenemia or DNAemia in routinely collected blood samples. The advantage of this strategy is that only high-risk patients are exposed to therapy. This would be expected to be associated with decreased cost and toxicity. Although this approach has been effective in bone marrow transplant patients, it is unclear whether pre-emptive therapy would be efficacious and cost-effective in lung transplant recipients. Several
Treatment
Standard therapy of CMV disease consists of 2 to 3 weeks of IV GCV at a dose of 5 mg/kg twice daily adjusted for renal insufficiency. Of some concern, Duncan et al2 found that treatment with IV GCV as monotherapy did not prevent the long-term sequelae of CMV. Although no controlled trials are available for the use of CMVIg for therapy in organ transplant recipients, many centers add it to their GCV for the treatment of tissue-invasive CMV pneumonia or colitis. Studies in bone marrow transplant
Antiviral resistance
Resistance of CMV to anti-viral agents has been well recognized in the laboratory and clinical setting and is a matter of growing concern in the management of solid organ transplant recipients.40 Infections due to GCV-resistant isolates have been reported in acquired immuno-deficiency syndrome (AIDS) patients, following bone marrow transplants and all solid organ transplants. The incidence of GCV resistance ranges from 2% to 10%, depending on the intensity of the immunosuppressive regimen and
Future directions in cytomegalovirus management
Most of the lung transplant literature to date has dealt with the prevention and treatment of the direct effects of CMV. What remains unanswered, is whether the prevention of the indirect effects of CMV proliferation, in regard to lung transplantation, is the prevention of BOS. It has been suggested that even asymptomatic viral proliferation may be associated with the development of BOS. Therefore, it would seem that prevention of any CMV proliferation, or treatment of asymptomatic infections
Conclusion
Lung transplant programs still need to refine the types of CMV prophylactic strategies that best match individual recipients of seropositive and seronegative allografts and the type of immunosuppression utilized. It seems clear that universal prophylaxis is warranted for high-risk D+/R− recipients. However, it remains unclear as to whether R+ recipients are also at higher risk than other solid organ recipients and whether they should receive universal prophylaxis or pre-emptive therapy. The use
References (47)
- et al.
Summary of the International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis of Cytomegalovirus Infection
Antiviral Res
(1996) - et al.
Use of the human cytomegalovirus (HCMV) antigenemia assay for diagnosis and monitoring of HCMV infections and detection of antiviral drug resistance in the immunocompromised
J Clin Virol
(1998) - et al.
Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients
J Heart Lung Transplant
(2001) - et al.
Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients
J Heart Lung Transplant
(2000) - et al.
Comparison of the efficacy and cost-effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients
J Heart Lung Transplant
(2000) Prevention and treatment of cytomegalovirus disease in heart transplant patients
J Heart Lung Transplant
(2000)- et al.
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants
Lancet
(2000) - et al.
Infection in organ-transplant recipients
N Engl J Med
(1998) - et al.
Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients
Am Rev Respir Dis
(1992) Infection in solid organ transplantation
Transplant Infect Dis
(1999)
The cost impact of cytomegalovirus disease in renal transplant recipients
Transplantation
Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients
Transplantation
The economic impact of cytomegalovirus infection after liver transplantation
Transplantation
Cytomegalovirus infections in heart and heart–lung transplant recipients
J Antimicrob Chemother
Lungs are a major organ site of cytomegalovirus latency and recurrence
J Virol
Influence of anti-rejection therapy on the timing of cytomegalovirus disease and other infections in renal transplant recipients
Clin Transplant
A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation
Am Rev Respir Dis
Influence of donor and recipient HLA locus mismatching on development of obliterative bronchiolitis after lung transplantation
Am J Respir Crit Care Med
Cytomegalovirus infection and pneumonitis
Am Rev Respir Dis
Development of bronchiolitis obliterans syndrome in recipients of heart–lung transplantation—early risk factors
Transplantation
Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patientsEvidence for a beneficial effect of hyperimmune globulin
Transplant Proc
Detection of human cytomegalovirus antigenemiaA rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients
Thorax
Detection of CMV pneumonitis after lung transplantation using PCR of DNA from bronchoalveolar lavage cells
Respiration
Cited by (46)
Opportunistic Infections Post-Lung Transplantation: Viral, Fungal, and Mycobacterial
2024, Infectious Disease Clinics of North AmericaOpportunistic Infections Post-Lung Transplantation: Viral, Fungal, and Mycobacterial
2023, Clinics in Chest MedicineManagement strategies for cytomegalovirus infection and disease in solid organ transplant recipients
2013, Infectious Disease Clinics of North AmericaCitation Excerpt :In this regard, kidney recipients with CMV are more likely to develop chronic allograft nephropathy (or tubulointerstitial fibrosis).41 Likewise, lung recipients with CMV are at increased risk of bronchiolitis obliterans,42 whereas heart recipients are at increased risk of accelerated coronary vasculopathy if they developed CMV infection and disease.43,44 CMV disease is associated with increased risk of death after SOT.11,38
Infections in heart and lung transplant recipients
2012, Clinical Microbiology NewsletterLung Transplant Complications
2012, Emergency Medicine: Clinical Essentials, SECOND EDITIONRecommendations for the use of extended criteria donors in lung transplantation
2011, Transplantation ProceedingsCitation Excerpt :Recipients with positive serology for hepatitis C or those vaccinated for hepatitis B may receive lungs of donors with positive serology for these diseases.24 The use of donors with positive serology (immunoglobulin G) for cytomegalovirus (CMV) in recipients with negative serology increases the risk of infection by CMV.25 There is controversy over the influence of CMV infection to produce an higher incidence of bronchiolitis obliterans.26,27